Printer Friendly

RICHARD C. WALOVITCH, PH.D., JOINS METASYN, INC. AS VICE PRESIDENT, PRECLINICAL AND CLINICAL RESEARCH

 CAMBRIDGE, Mass., June 14 /PRNewswire/ -- Metasyn, Inc. announced today that Richard C. Walovitch, Ph.D., has joined the company as vice president, Preclinical and Clinical Research. Dr. Walovitch joins Metasyn from Du Pont Merck Pharmaceutical Co. where he was global project clinician for Neurolite(R), a brain imaging agent.
 "Rick Walovitch brings to Metasyn enormous expertise in the development of advanced imaging agents," commented Randall B. Lauffer, Ph.D., chairman and CEO of Metasyn. "At Du Pont Merck, he successfully guided the preclinical and clinical development, through FDA and European Community filing, of Neurolite, an innovative stroke imaging agent. His appointment also reflects Metasyn's progress in developing tissue-specific contrast agents for magnetic resonance imaging." Dr. Lauffer noted that the company's first product, a liver-enhancing agent for the early detection of liver metastases, is expected to enter clinical trials in 1994.
 Dr. Walovitch served for eight years at Du Pont Merck and its predecessor Du Pont Pharmaceuticals. He joined Du Pont's Division of Radiopharmaceutical Research as a research pharmacologist in 1985, following a post-doctoral fellowship at the National Institute on Drug Abuse. Dr. Walovitch received both his doctorate degree in pharmacology and a bachelor of science degree in biology from the University of Illinois.
 Metasyn, Inc. is engaged in the discovery and development of new diagnostic and therapeutic pharmaceuticals based on inorganic chemistry, the chemistry of metal ions and organic complexing agents. The company is based in Cambridge, Mass.
 -0- 6/14/93
 /CONTACT: Randall B. Lauffer, Ph.D., chairman and CEO, Metasyn, Inc., 617-499-1400; Robert Gottlieb, senior vice president, Feinstein Partners Inc., 617-577-8110, for Metasyn/


CO: Metasyn, Inc. ST: Massachusetts IN: MTC SU: PER

CM -- NE003 -- 1486 06/14/93 09:49 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 14, 1993
Words:283
Previous Article:ORTHOMET ANNOUNCES NEW CONTRACT WITH CHAIRMAN AND CEO
Next Article:VIEWLOGIC "POWERPARTNERS" PR0GRAM OFFERS EDA VENDORS CFI-BASED FRAMEWORK TECHNOLOGY; TWENTY-NINE EDA VENDORS SIGN ON AS POWERPARTNERS
Topics:


Related Articles
METASYN, INC. COMPLETES $4 MILLION SECOND ROUND FINANCING
METASYN, INC. PRESENTS PRECLINICAL DATA ON LIVER AND TUMOR MRI CONTRAST AGENTS FOR CANCER DETECTION AND STAGING
METASYN, INC. RECEIVES TWO NIH GRANTS TO DEVELOP TARGETED MRI CONTRAST AGENTS FOR CANCER DETECTION AND STAGING
MICHAEL D. WEBB JOINS METASYN, INC. AS PRESIDENT AND CHIEF EXECUTIVE OFFICER
METASYN, INC. APPOINTS SUSAN M. FLINT AS VICE PRESIDENT, REGULATORY AFFAIRS
JAMES S. FARINA JOINS METASYN, INC. AS SENIOR DIRECTOR, CHEMICAL AND ANALYTICAL DEVELOPMENT
METASYN SIGNS $12 MILLION PARTNERSHIP WITH DAIICHI RADIOISOTOPE OF JAPAN
METASYN POSITIONS FOR UPCOMING U.S. CLINICAL TRIALS, STRENGTHENS MANAGEMENT TEAM
Mallinckrodt, METASYN Form Strategic Alliance
James G. McArthur, Ph.D. Joins Phylogix as Vice President Research and Preclinical Development.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters